Tiludronate has been used to treat bone spavin and navicular disease in Europe for many years and was licensed for bone spavin in the UK in 2008. The treatment is designed to regulate and improve the bone remodelling occurring in the layer of bone just below the cartilage and next to arthritic joints. It works by helping to adjust and rebalance the natural remodelling and removal of the bone structures and alleviate pain.
In simple terms bones remodel all the time but with osteoarthritic conditions such as bone spavin the bone-producing cells (oesteoblasts) can’t keep up with the bone-removing cells (osteoclasts), which can work up to ten times faster. Equidronate® actually helps to stop the osteoclasts from continuing to disrupt the bones within the joints. It prevents further damage and gives the osteoblasts a chance to catch up and repair the problem. This, in combination with adjusting the levels of exercise, helps to harmonise the bone adaptation needed for the horse to perform its athletic duties.
Trials published last year show that horses suffering lameness caused by bone spavin can show marked improvement following treatment with an Equidronate® infusion, in combination with controlled exercise. One in four horses showed marked improvement; two in four showed improvement, which, when combined with other treatment, enabled the horse to resume former levels of activity and one in four horses showed no response.
Ceva Animal Health has produced a range of explanatory leaflets for horse owners on bone spavin, navicular disease and sacroiliac disease, as well as a helpful booklet detailing the discharge procedures for horses that have been treated with Equidronate®. Advice on this product must be sought from your vet. Further information on request from Ceva Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG or www.tildren.com.